ATE382057T1 - Stabile formulierung von modifiziertem glp-1 - Google Patents

Stabile formulierung von modifiziertem glp-1

Info

Publication number: ATE382057T1
Authority: AT; Austria
Prior art keywords: stable formulation; modified glp; glp; modified; formulation
Prior art date: 2001-06-28

Application number

AT02745182T

Other languages

English (en)

Inventor

James Flink

Silke Larsen

Simon Jensen

Dorthe Engelund

Original Assignee

Novo Nordisk As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-06-28

Filing date

2002-06-27

Publication date

2008-01-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27545250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE382057(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-06-27 Application filed by Novo Nordisk As filed Critical Novo Nordisk As

2008-01-15 Application granted granted Critical

2008-01-15 Publication of ATE382057T1 publication Critical patent/ATE382057T1/de

Links

DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title abstract 2
238000009472 formulation Methods 0.000 title 1
239000000203 mixture Substances 0.000 title 1
238000000034 method Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Endocrinology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Obesity (AREA)
Toxicology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Immunology (AREA)
Emergency Medicine (AREA)
Dermatology (AREA)
Child & Adolescent Psychology (AREA)
Inorganic Chemistry (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)

AT02745182T 2001-06-28 2002-06-27 Stabile formulierung von modifiziertem glp-1 ATE382057T1 (de)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
DKPA200101011		2001-06-28
DKPA200101010		2001-06-28
DKPA200101052		2001-07-04
DKPA200101053		2001-07-04
DKPA200200093		2002-01-18
DKPA200200092		2002-01-18

Publications (1)

Publication Number	Publication Date
ATE382057T1 true ATE382057T1 (de)	2008-01-15

Family

ID=27545250

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02745182T ATE382057T1 (de)	2001-06-28	2002-06-27	Stabile formulierung von modifiziertem glp-1

Country Status (10)

Country	Link
US (4)	US20030119734A1 (de)
EP (1)	EP1412384B1 (de)
JP (2)	JP5562510B2 (de)
AT (1)	ATE382057T1 (de)
AU (1)	AU2002316811A1 (de)
DE (1)	DE60224284T2 (de)
DK (1)	DK1412384T3 (de)
ES (1)	ES2298378T3 (de)
PT (1)	PT1412384E (de)
WO (1)	WO2003002136A2 (de)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2686899B1 (fr)	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6558952B1 (en) *	1992-12-14	2003-05-06	Waratah Pharmaceuticals, Inc.	Treatment for diabetes
US20040037818A1 (en) *	1998-07-30	2004-02-26	Brand Stephen J.	Treatment for diabetes
EP1274720A4 (de)	2000-04-12	2004-08-18	Human Genome Sciences Inc	Albumin enthaltende fusionsproteine
US20030119734A1 (en) *	2001-06-28	2003-06-26	Flink James M.	Stable formulation of modified GLP-1
PT1463751E (pt)	2001-12-21	2013-08-26	Human Genome Sciences Inc	Proteínas de fusão de albumina
US7635463B2 (en)	2002-02-27	2009-12-22	Pharmain Corporation	Compositions for delivery of therapeutics and other materials
CA2476589C (en) *	2002-02-27	2014-02-25	Pharmain, Ltd.	Compositions for delivery of therapeutics and other materials, and methods of making and using the same
ES2615484T3 (es)	2002-05-21	2017-06-07	Daiichi Sankyo Company, Limited	Composiciones medicinales que contienen grelina
IL165242A0 (en) *	2002-05-24	2005-12-18	Waratah Pharmaceuticals Inc	Treatment for diabetes
KR20050048542A (ko)	2002-06-07	2005-05-24	와라타 파마수티컬즈, 인크.	당뇨병의 치료를 위한 조성물 및 방법
MXPA05004202A (es) *	2002-10-22	2005-09-20	Waratah Pharmaceuticals Inc	Tratamiento de la diabetes.
CA2513213C (en)	2003-01-22	2013-07-30	Human Genome Sciences, Inc.	Albumin fusion proteins
CN1771080B (zh)	2003-04-08	2010-12-15	诺沃挪第克公司	包括至少一个色谱处理步骤的生产治疗用多肽或其前体的方法
WO2004089985A1 (en)	2003-04-11	2004-10-21	Novo Nordisk A/S	Stable pharmaceutical compositions
CN1822851B (zh)	2003-05-15	2011-04-13	塔夫茨大学信托人	肽和多肽药物的稳定类似物
WO2004105781A2 (en) *	2003-06-03	2004-12-09	Novo Nordisk A/S	Stabilized pharmaceutical peptide compositions
WO2004105790A1 (en)	2003-06-03	2004-12-09	Novo Nordisk A/S	Stabilized pharmaceutical peptide compositions
JP4936884B2 (ja)	2003-06-03	2012-05-23	ノボ・ノルデイスク・エー／エス	安定化された薬学的ペプチド組成物
EP2107069B1 (de)	2003-08-05	2013-01-16	Novo Nordisk A/S	Neuartige Insulinderivate
CN100535007C (zh) *	2003-08-21	2009-09-02	诺沃挪第克公司	胰高血糖素样肽的纯化
US20060247167A1 (en) *	2003-09-01	2006-11-02	Novo Nordisk A/S	Stable formulations of peptides
EP1663295A2 (de) *	2003-09-01	2006-06-07	Novo Nordisk A/S	Stabilisierte peptidformulierungen
WO2005023291A2 (en) *	2003-09-11	2005-03-17	Novo Nordisk A/S	Use of glp1-agonists in the treatment of patients with type i diabetes
TW200522976A (en)	2003-09-19	2005-07-16	Novo Nordisk As	Novel plasma protein affinity tags
RU2401276C2 (ru) *	2003-09-19	2010-10-10	Ново Нордиск А/С	Производные глюкагон-подобного пептида-1 (glp-1)
KR101241862B1 (ko) *	2003-09-19	2013-03-13	노보 노르디스크 에이/에스	신규 ｇｌｐ-1 유도체
PT1687019T (pt) *	2003-11-20	2018-02-26	Novo Nordisk As	Formulações de péptidos que contêm polietileno glicol que são ótimas para produção e para utilização em dispositivos de injeção
WO2005056036A2 (en)	2003-12-09	2005-06-23	Novo Nordisk A/S	Regulation of food preference using glp-1 agonists
CA2550695A1 (en) *	2003-12-16	2005-06-30	Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R	Glp-1 pharmaceutical compositions
US20060210614A1 (en) *	2003-12-26	2006-09-21	Nastech Pharmaceutical Company Inc.	Method of treatment of a metabolic disease using intranasal administration of exendin peptide
US20050143303A1 (en) *	2003-12-26	2005-06-30	Nastech Pharmaceutical Company Inc.	Intranasal administration of glucose-regulating peptides
US20080318837A1 (en) *	2003-12-26	2008-12-25	Nastech Pharmaceutical Company Inc.	Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
US20060074025A1 (en) *	2003-12-26	2006-04-06	Nastech Pharmaceutical Company Inc.	Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability
US20090202494A1 (en) *	2004-01-30	2009-08-13	Antonio Cruz	Combined use of glp-1 agonists and gastrin for regulating blood glucose levels
WO2005112977A2 (en) *	2004-04-23	2005-12-01	Pharmain, Ltd.	Compositions for treatment with glucagon-like peptide, and methods of making and using the same
EP1758575A1 (de)	2004-06-11	2007-03-07	Novo Nordisk A/S	Bekämpfung von arzneimittel-induzierter fettleibigkeit unter verwendung von glp-1-agonisten
KR101149454B1 (ko) *	2004-08-24	2012-05-25	간가와 겐지	생리활성 펩티드의 액상 제제
EP1789434B1 (de)	2004-08-31	2013-11-20	Novo Nordisk A/S	Verwendung von tris(hydroxymethyl)-aminomethan zur stabilisierung von peptiden, polypeptiden und proteinen
EP2330126B1 (de)	2004-10-07	2015-12-23	Novo Nordisk A/S	Exendin-4-Zusammensetzungen mit verlängerter Halbwertszeit
JP2008515856A (ja)	2004-10-07	2008-05-15	ノボノルディスクアクティーゼルスカブ	遅延性ｇｌｐ−１化合物
EP2494983B1 (de) *	2004-11-12	2019-04-24	Novo Nordisk A/S	Stabile formulierung von glp-1
BRPI0518761A2 (pt)	2004-12-02	2008-12-09	Domantis Ltd	fusço de droga, conjugado de droga, Ácido nucleico recombinante, construÇço de Ácido nucleico, cÉlula hospedeira, mÉtodo para produzir uma fusço de droga, composiÇço farmacÊutica, droga, mÉtodo de tratamento e/ou prevenÇço de uma condiÇço em um paciente, mÉtodo de retardo ou prevenÇço de progressço de doenÇa, e, mÉtodo para diminuir a absorÇço de alimentos por um paciente
ES2343641T3 (es)	2005-01-14	2010-08-05	Camurus Ab	Formulaciones bioadhesivas topicas.
PL1843746T3 (pl)	2005-01-14	2011-09-30	Camurus Ab	Formulacje analogów somatostatyny
US9649382B2 (en)	2005-01-14	2017-05-16	Camurus Ab	Topical bioadhesive formulations
WO2006077362A1 (en)	2005-01-21	2006-07-27	Camurus Ab	Pharmaceutical lipid compositions
TWI372629B (en)	2005-03-18	2012-09-21	Novo Nordisk As	Acylated glp-1 compounds
JP5755398B2 (ja) *	2005-03-18	2015-07-29	ノヴォノルディスクアー／エス	伸長されたｇｌｐ−１化合物
EP1889618A4 (de) *	2005-05-27	2010-11-24	Daiichi Sankyo Co Ltd	Kombiniertes arzneimittel zur behandlung von diabetes
US8097239B2 (en)	2005-06-06	2012-01-17	Camurus Ab	Controlled-release formulations
CN101217940B (zh)	2005-06-06	2013-03-27	卡穆鲁斯公司	Glp-1类似物制剂
RS51319B (sr)	2005-09-22	2010-12-31	Biocompatibles Uk Limited	GLP-l (GLUKAGON-LIKE PEPTID-l) FUZIONI POLIPEPTIDI SA POVEĆANOM OTPORNOSTI NA PEPTIDAZE
WO2007067964A2 (en) *	2005-12-08	2007-06-14	Nastech Pharmaceutical Company Inc.	Mucosal delivery of stabilized formulations of exendin
EP1971372B1 (de)	2005-12-19	2018-11-14	PharmaIN Corporation	Trägerzusammensetzungen mit hydrophobem kern zur abgabe von therapeutischen mitteln, herstellungs- und anwendungsverfahren damit
US20090074882A1 (en)	2005-12-28	2009-03-19	Novo Nordisk A/S	Insulin compositions and method of making a composition
EP1854455B1 (de)	2006-05-10	2009-10-07	Biocompatibles UK Limited	GLP-1 Peptide enthaltende kugelförmige Mikrokapseln, deren Produktion und deren Verwendung
JP5552046B2 (ja)	2007-06-13	2014-07-16	ノボ・ノルデイスク・エー／エス	インスリン誘導体を含有する薬学的製剤
GB0711656D0 (en)	2007-06-15	2007-07-25	Camurus Ab	Formulations
US7960336B2 (en)	2007-08-03	2011-06-14	Pharmain Corporation	Composition for long-acting peptide analogs
US8563527B2 (en) *	2007-08-20	2013-10-22	Pharmain Corporation	Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
GB0716385D0 (en)	2007-08-22	2007-10-03	Camurus Ab	Formulations
US20090176892A1 (en)	2008-01-09	2009-07-09	Pharmain Corporation	Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
KR20100132535A (ko)	2008-03-31	2010-12-17	글락소 그룹 리미티드	약물 융합체 및 컨주게이트
AU2009279090A1 (en)	2008-08-06	2010-02-11	Novo Nordisk Health Care Ag	Conjugated proteins with prolonged in vivo efficacy
GB0815435D0 (en)	2008-08-22	2008-10-01	Camurus Ab	Formulations
EP2163243A1 (de) *	2008-09-12	2010-03-17	Biocompatibles UK Limited	Behandlung akuter Herzinfarkte mithilfe eingekapselter Zellen, welche GLP-1-Peptide oder deren Analoga kodieren und absondern
KR20110085985A (ko)	2008-10-30	2011-07-27	노보 노르디스크 에이/에스	하루 한번 주사 빈도보다 적은 인슐린 주사를 사용한 진성 당뇨병의 치료
WO2010063818A2 (en)	2008-12-05	2010-06-10	Glaxo Group Limited	Methods for selecting protease resistant polypeptides
CA2747825A1 (en)	2009-01-22	2010-07-29	Novo Nordisk Health Care Ag	Stable growth hormone compounds
PE20120514A1 (es)	2009-03-27	2012-05-14	Glaxo Group Ltd	Fusiones y conjugados de agentes insulinotropicos o farmacos incretina con anticuerpos dab anti-albumina serica
EP2461831B1 (de)	2009-08-06	2018-11-21	Novo Nordisk Health Care AG	Wachstumshormone mit verlängerter in-vivo-wirksamkeit
SG10201406063XA (en)	2009-09-30	2014-11-27	Glaxo Group Ltd	Drug fusions and conjugates with extended half life
RU2012134974A (ru)	2010-01-22	2014-02-27	Ново Нордиск Хелс Кеа Аг	Стабилизированное соединение гормона роста
RU2605627C2 (ru)	2010-01-22	2016-12-27	Ново Нордиск Хелс Кеа Аг	Гормоны роста с пролонгированной эффективностью in vivo
US9168288B2 (en)	2010-04-09	2015-10-27	Mount Sinai Hospital	Methods for treating disorders of the gastrointestinal tract using a GLP-1 agonist
BR112013010345A2 (pt)	2010-10-27	2017-07-25	Novo Nordisk As	tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção
WO2012136790A1 (en)	2011-04-07	2012-10-11	Glaxo Group Limited	Compositions comprising fusion proteins or conjugates with an improved half -life
WO2012136792A2 (en)	2011-04-07	2012-10-11	Glaxo Group Limited	Cck compositions
CN104244981A (zh)	2011-12-09	2014-12-24	诺和诺德A/S	Glp-1激动剂
AU2013265210B2 (en)	2012-05-25	2016-09-15	Camurus Ab	Somatostatin receptor agonist formulations
RS67258B1 (sr)	2012-07-01	2025-10-31	Novo Nordisk As	Upotreba dugodelujućih glp-1 peptida
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
JP2016506401A (ja)	2012-12-21	2016-03-03	サノフイ	二重ｇｌｐ１／ｇｉｐまたは三方ｇｌｐ１／ｇｉｐ／グルカゴンアゴニストとしてのエキセンジン−４誘導体
CN103893744B (zh) *	2012-12-24	2017-12-19	杭州九源基因工程有限公司	一种治疗糖尿病的药物制剂及其制备方法
EP2981282B1 (de)	2013-04-05	2020-11-04	Novo Nordisk Health Care AG	Wachstumshormonverbindungsformulierung
JP2016519127A (ja)	2013-04-30	2016-06-30	ノヴォノルディスクアー／エス	新規投与レジメン
CN103405753B (zh) *	2013-08-13	2016-05-11	上海仁会生物制药股份有限公司	稳定的促胰岛素分泌肽水针药物组合物
EP3080150B1 (de)	2013-12-13	2018-08-01	Sanofi	Exendin-4-peptidanaloga als duale glp-1/gip-rezeptoragonisten
WO2015086733A1 (en)	2013-12-13	2015-06-18	Sanofi	Dual glp-1/glucagon receptor agonists
TW201609799A (zh)	2013-12-13	2016-03-16	賽諾菲公司	雙重ｇｌｐ－１／ｇｉｐ受體促效劑
TW201609796A (zh)	2013-12-13	2016-03-16	賽諾菲公司	非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TWI668010B (zh) *	2014-05-07	2019-08-11	丹麥商諾佛儂迪克股份有限公司	使用ｇｌｐ－１及抗ｉｌ－２１治療糖尿病
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
WO2016038521A1 (en) *	2014-09-08	2016-03-17	Sun Pharmaceutical Industries Limited	Pharmaceutical compositions of liraglutide
CN104800572A (zh) *	2015-04-20	2015-07-29	陈兴田	一种治疗伴抑郁焦虑状态的功能性消化不良的中药制剂
CN107249620B (zh) *	2015-05-13	2018-06-26	杭州九源基因工程有限公司	一种包含glp-1类似物的药物制剂及其制备方法
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh)	2015-07-10	2017-02-16	賽諾菲公司	作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
EP3424521A4 (de) *	2016-03-01	2019-12-18	Hybio Pharmaceutical Co., Ltd	Pharmazeutische zusammensetzung und herstellungsverfahren dafür
US12569543B2 (en) *	2016-04-28	2026-03-10	Novo Nordisk A/S	Semaglutide in cardiovascular conditions
US20190224122A1 (en)	2016-09-23	2019-07-25	Delpor, Inc.	Stable compositions for incretin mimetic compounds
HUE066356T2 (hu)	2017-08-24	2024-07-28	Novo Nordisk As	GLP-1 készítmények és alkalmazásaik
WO2019060735A1 (en)	2017-09-21	2019-03-28	EMULATE, Inc.	PHYSIOLOGY AND PATHOPHYSIOLOGY OF HUMAN INTESTINES: INTESTIN-ON-CHIP
IL322969A (en)	2017-10-12	2025-10-01	Novo Nordisk As	Semaglutide in medical therapy
TWI705820B (zh)	2018-06-22	2020-10-01	美商美國禮來大藥廠	Gip/glp1促效劑組合物
US10335464B1 (en)	2018-06-26	2019-07-02	Novo Nordisk A/S	Device for titrating basal insulin
IL281938B2 (en)	2018-10-26	2024-04-01	Novo Nordisk As	Stable semaglutide compositions and uses thereof
WO2020127476A1 (en)	2018-12-19	2020-06-25	Krka, D.D., Novo Mesto	Pharmaceutical composition comprising glp-1 analogue
WO2020208541A1 (en)	2019-04-08	2020-10-15	Enzene Biosciences Limited	Composition comprising glp-1 analogue
US12343383B2 (en)	2019-07-12	2025-07-01	Novo Nordisk A/S	High concentration insulin formulation
US20220372072A1 (en) *	2019-09-19	2022-11-24	Dr. Reddy's Laboratories Limited	Improved purification processes for liraglutide
GB201917723D0 (en) *	2019-12-04	2020-01-15	Nv Rose Llc	Stable liquid formulations of glucagon-like peptide 1 or analogues thereof
WO2021123228A1 (en)	2019-12-18	2021-06-24	Krka, D.D., Novo Mesto	Pharmaceutical composition comprising glp-1 analogue
PE20221575A1 (es) *	2020-02-18	2022-10-06	Novo Nordisk As	Formulaciones farmaceuticas
AU2021274518A1 (en) *	2020-05-22	2023-01-19	Hanmi Pharm. Co., Ltd.	Liquid preparation of long-acting conjugate of glucagon/GLP-1/GIP trigonal agonist
AU2022263996A1 (en)	2021-04-27	2023-11-02	Aardvark Therapeutics, Inc.	Combination of bitter receptor agonist and gut-signaling compound
WO2022228498A1 (zh) *	2021-04-30	2022-11-03	信达生物制药(苏州)有限公司	一种oxm3储存剂、oxm3制剂及制备方法
CN113249288B9 (zh) *	2021-07-13	2021-11-09	奥锐特药业(天津)有限公司	一种表达glp-1类似物的重组菌及其应用

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4483849A (en)	1983-01-07	1984-11-20	Carter William A	Stabilization and purification of interferon with propylene glycol, resulting in a non-toxic product
US4468346A (en)	1983-10-27	1984-08-28	The United States Of America As Represented By The Secretary Of Agriculture	Monoclonal antibodies to porcine immunoglobulins
AU616411B2 (en)	1987-05-14	1991-10-31	Commonwealth Scientific And Industrial Research Organisation	Whey protein fractions
JPH03505401A (ja)	1988-06-27	1991-11-28	ジェネックス・コーポレーション	組換えタンパク質の培養培地への熱放出
DE69013471T2 (de)	1989-12-05	1995-03-30	Merck & Co Inc	Methode zur Stabilisierung von rekombinanten Hepatitis-B-Virus-Oberflächenproteinen aus Hefe.
DE4002066A1 (de)	1990-01-25	1991-08-01	Basf Ag	Verfahren zur abtrennung von riboflavin aus fermentationssuspensionen
US5272135A (en)	1991-03-01	1993-12-21	Chiron Ophthalmics, Inc.	Method for the stabilization of methionine-containing polypeptides
SE9101381D0 (sv)	1991-05-07	1991-05-07	Tomas Moks	Peptide hormone solution
US5206219A (en)	1991-11-25	1993-04-27	Applied Analytical Industries, Inc.	Oral compositions of proteinaceous medicaments
DK36492D0 (da)	1992-03-19	1992-03-19	Novo Nordisk As	Praeparat
SG45449A1 (en)	1992-05-13	1998-01-16	Sandoz Ltd	Ophthalmic compositions
US6284727B1 (en)	1993-04-07	2001-09-04	Scios, Inc.	Prolonged delivery of peptides
AU7531094A (en)	1993-08-24	1995-03-21	Novo Nordisk A/S	Protracted glp-1
GB9320782D0 (en)	1993-10-08	1993-12-01	Univ Leeds Innovations Ltd	Stabilising of proteins on solution
CA2176462A1 (en)	1993-11-19	1995-05-26	Larry P. Feigen	Transdermal composition of n-[n-[5-[4-(aminoiminomethyl)phenyl]-1-oxopentyl]-l-.alpha.-aspartyl]-l-phenylalanine or its esters and their pharmaceutically acceptable salts
US5705483A (en)	1993-12-09	1998-01-06	Eli Lilly And Company	Glucagon-like insulinotropic peptides, compositions and methods
WO1995022560A1 (en)	1994-02-22	1995-08-24	The Syntex-Synergen Neuroscience Joint Venture	Pharmaceutical formulations of cntf
US5652216A (en) *	1994-05-26	1997-07-29	Novo Nordisk A/S	Pharmaceutical preparation
CA2157219C (en)	1994-08-31	2010-10-05	Munehiro Noda	Process for purifying recombinant human serum albumin
US5512549A (en) *	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
WO1996020005A1 (en) *	1994-12-23	1996-07-04	Novo Nordisk A/S	Protracted glp-1 compositions
JP2000510813A (ja)	1995-02-06	2000-08-22	ジェネテイックス・インスティテュート・インコーポレイテッド	Ｉｌ−１２用処方
US5869602A (en) *	1995-03-17	1999-02-09	Novo Nordisk A/S	Peptide derivatives
US5834428A (en)	1995-04-14	1998-11-10	1149336 Ontario Inc.	Glucagon-like peptide-2 and its therapeutic use
US6184201B1 (en)	1995-04-14	2001-02-06	Nps Allelix Corp.	Intestinotrophic glucagon-like peptide-2 analogs
AU5996996A (en)	1995-06-02	1996-12-18	Novo Nordisk A/S	Al/fe-treatment of a protein solution, followed by membrane concentration
US5631347A (en)	1995-06-07	1997-05-20	Eli Lilly And Company	Reducing gelation of a fatty acid-acylated protein
CZ433898A3 (cs)	1996-07-03	1999-04-14	Alza Corporation	Nevodné protické peptidové formulace
JPH10101696A (ja)	1996-08-08	1998-04-21	Shinotesuto:Kk	形質転換体にて発現される蛋白質に含まれる夾雑物質の除去方法及び精製蛋白質
JP3149958B2 (ja) *	1996-08-30	2001-03-26	ノボノルディスクアクティーゼルスカブ	Ｇｌｐ―１誘導体
US6268343B1 (en) *	1996-08-30	2001-07-31	Novo Nordisk A/S	Derivatives of GLP-1 analogs
KR20000070338A (ko)	1997-01-20	2000-11-25	나가시마 카쭈시게, 노미야마 아키히코	펩티드의 안정화 방법 및 당해 방법을 이용한 펩티드 함유 동결건조 의약조성물
CA2236519C (en)	1997-05-02	2011-09-13	1149336 Ontario Inc.	Methods of enhancing functioning of the large intestine
ZA984697B (en)	1997-06-13	1999-12-01	Lilly Co Eli	Stable insulin formulations.
CA2306024C (en)	1997-10-01	2011-04-26	Flemington Pharmaceutical Corporation	Buccal, polar and non-polar spray or capsule
WO1999021889A1 (en)	1997-10-24	1999-05-06	Genentech, Inc.	Purification of molecules
CA2312190A1 (en)	1997-12-05	1999-06-17	Eli Lilly And Company	Glp-1 formulations
DE29721752U1 (de)	1997-12-09	1998-02-12	Siemens AG, 80333 München	Crimpkontakt für Stecksysteme
US6380357B2 (en)	1997-12-16	2002-04-30	Eli Lilly And Company	Glucagon-like peptide-1 crystals
JP2002504518A (ja) *	1998-02-27	2002-02-12	ノボノルディスクアクティーゼルスカブ	部分的に構造化されたミセルー様凝集体を形成する、２５％を超えるヘリックス−含有率を有するｇｌｐ−１誘導体
WO1999043706A1 (en) *	1998-02-27	1999-09-02	Novo Nordisk A/S	Derivatives of glp-1 analogs
WO1999043708A1 (en)	1998-02-27	1999-09-02	Novo Nordisk A/S	Glp-1 derivatives of glp-1 and exendin with protracted profile of action
AU2610899A (en)	1998-02-27	1999-09-15	Novo Nordisk A/S	N-terminally modified glp-1 derivatives
ATE269103T1 (de) *	1998-03-13	2004-07-15	Novo Nordisk As	Stabilisierte wässerige glukagonlösungen enthaltend detergenzien
US6245572B1 (en)	1998-05-01	2001-06-12	University Of Tennessee Research Corporation	Flow cytometric characterization of amyloid fibrils
BR9913857A (pt) *	1998-09-17	2001-06-12	Lilly Co Eli	Formulações de proteìna
CA2358107C (en)	1998-12-22	2011-08-23	Eli Lilly And Company	Shelf-stable formulation of glucagon-like peptide-1
CN101181236A (zh)	1999-01-14	2008-05-21	安米林药品公司	新型exendin激动剂制剂及其给药方法
US6444788B1 (en)	1999-03-15	2002-09-03	Novo Nordisk A/S	Ion exchange chromatography of GLP-1, analogs and derivatives thereof
HUP0200297A3 (en) *	1999-03-17	2002-09-30	Novo Nordisk As	Method for acylating peptides and the glutaminic acid derivatives as acylating agents
CA2369839A1 (en)	1999-06-25	2001-01-04	Minimed, Inc.	Compositions of insulin and insulin-related peptide for treating diabetes
EP1076066A1 (de)	1999-07-12	2001-02-14	Zealand Pharmaceuticals A/S	Peptide zur Senkung des Blutglukosespiegels
US6569832B1 (en)	1999-11-12	2003-05-27	Novo Nordisk A/S	Inhibition of beta cell degeneration
DE60018105T2 (de)	1999-12-16	2005-12-29	Eli Lilly And Co., Indianapolis	Polypeptidzusammensetzungen mit verbesserter stabilität
US7022674B2 (en)	1999-12-16	2006-04-04	Eli Lilly And Company	Polypeptide compositions with improved stability
GB9930882D0 (en)	1999-12-30	2000-02-23	Nps Allelix Corp	GLP-2 formulations
AU2353701A (en)	2000-01-11	2001-07-24	Novo Nordisk A/S	Transepithelial delivery of glp-1 derivatives
WO2001052937A1 (en)	2000-01-24	2001-07-26	Medtronic Minimed, Inc.	Mixed buffer system for stabilizing polypeptide formulations
HUP0204281A3 (en)	2000-01-27	2007-03-28	Lilly Co Eli	Process for sulubilizing glucagon-like peptide 1 (glp-1) compounds
EP1396499A3 (de)	2000-01-27	2004-12-29	Eli Lilly And Company	Verfahren zur Lösung von Glucagon-ähnlichen Peptid-1 (GLP-1) Verbindungen
US6569901B2 (en)	2000-01-28	2003-05-27	Novo Nordisk A/S	Alkynyl-substituted propionic acid derivatives, their preparation and use
US6844321B2 (en)	2000-01-31	2005-01-18	Novo Nordisk A/S	Crystallization of a GLP-1 analogue
WO2001077141A1 (en)	2000-04-06	2001-10-18	Novo Nordisk A/S	Shock heat treatment of polypeptides
PT1695983E (pt)	2000-06-16	2009-05-05	Lilly Co Eli	Análogos do peptídeo-1 do tipo glucagon
JP4798833B2 (ja)	2000-10-24	2011-10-19	一般財団法人化学及血清療法研究所	加熱処理工程を含むヒト血清アルブミンの製造方法
EP2186824A3 (de)	2000-12-13	2010-09-22	Eli Lilly & Company	Chronisches Behandlungsschema mit Glucagon-ähnlichen insulinotropischen Peptiden
US7199217B2 (en)	2000-12-13	2007-04-03	Eli Lilly And Company	Amidated glucagon-like peptide-1
US20020151467A1 (en)	2000-12-21	2002-10-17	Leung Frank K.	Methods and compositions for oral insulin delivery
GB2371227A (en)	2001-01-10	2002-07-24	Grandis Biotech Gmbh	Crystallisation - resistant aqueous growth hormone formulations
ATE396202T1 (de)	2001-02-16	2008-06-15	Conjuchem Biotechnologies Inc	Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen
WO2002069994A2 (en)	2001-03-07	2002-09-12	Novo Nordisk A/S	Combined use of derivatives of glp-1 analogs and ppar ligands
US6573237B2 (en)	2001-03-16	2003-06-03	Eli Lilly And Company	Protein formulations
EP1391209A4 (de)	2001-05-30	2009-12-16	Chugai Pharmaceutical Co Ltd	Proteinzubereitung
US20030119734A1 (en)	2001-06-28	2003-06-26	Flink James M.	Stable formulation of modified GLP-1
CN1335182A (zh)	2001-08-08	2002-02-13	华中科技大学	胰岛素口腔喷剂及其制备工艺
CA2452044A1 (en)	2001-08-28	2003-03-13	Eli Lilly And Company	Pre-mixes of glp-1 and basal insulin
CA2463803A1 (en)	2001-10-19	2003-05-01	Eli Lilly And Company	Biphasic mixtures of glp-1 and insulin
PT1344533E (pt)	2002-03-15	2007-01-31	Natimmune As	Composições farmacêuticas compreendendo lectina de ligação a manose
JP2005535569A (ja) *	2002-04-04	2005-11-24	ノボ・ノルデイスク・エー／エス	Ｇｌｐ−１アゴニスト及び心臓血管合併症
DE60321473D1 (de)	2002-09-25	2008-07-17	Novo Nordisk As	Aufreinigungsverfahren, das eine mikrofiltration bei erhöhten temperaturen beinhaltet
US7273921B2 (en)	2002-09-25	2007-09-25	Novo Nordisk A/S	Method for producing acylated peptides
WO2004089985A1 (en)	2003-04-11	2004-10-21	Novo Nordisk A/S	Stable pharmaceutical compositions
ES2425221T3 (es)	2003-05-30	2013-10-14	Amylin Pharmaceuticals, Llc	Nuevos métodos y composiciones para suministro por vía transmucosa potenciado de péptidos y proteínas
WO2004105781A2 (en)	2003-06-03	2004-12-09	Novo Nordisk A/S	Stabilized pharmaceutical peptide compositions
US20060287221A1 (en)	2003-11-13	2006-12-21	Novo Nordisk A/S	Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
ES2373660T3 (es)	2003-11-13	2012-02-07	Novo Nordisk A/S	Composición farmacéutica que comprende un análogo insulinotrópico de glp-1 (7-37), insulina asp(b28) y un tensioactivo.
PT1687019T (pt) *	2003-11-20	2018-02-26	Novo Nordisk As	Formulações de péptidos que contêm polietileno glicol que são ótimas para produção e para utilização em dispositivos de injeção
EP1789075A4 (de)	2004-08-25	2009-07-01	Uab Research Foundation	Absorptionsverbesserer für die arzneimittelverabreichung
JP5248113B2 (ja)	2004-11-12	2013-07-31	ノヴォノルディスクアー／エス	ペプチドの安定な処方
WO2008011446A2 (en) *	2006-07-18	2008-01-24	Centocor, Inc.	Human glp-1 mimetibodies, compositions, methods and uses
TW200843794A (en) *	2006-12-21	2008-11-16	Centocor Inc	Use of long-acting GLP-1 receptor agonists to improve insulin sensitivity and lipid profiles

2002
- 2002-06-27 US US10/185,923 patent/US20030119734A1/en not_active Abandoned
- 2002-06-27 DK DK02745182T patent/DK1412384T3/da active
- 2002-06-27 JP JP2003508375A patent/JP5562510B2/ja not_active Expired - Lifetime
- 2002-06-27 AU AU2002316811A patent/AU2002316811A1/en not_active Abandoned
- 2002-06-27 AT AT02745182T patent/ATE382057T1/de active
- 2002-06-27 PT PT02745182T patent/PT1412384E/pt unknown
- 2002-06-27 ES ES02745182T patent/ES2298378T3/es not_active Expired - Lifetime
- 2002-06-27 EP EP02745182A patent/EP1412384B1/de not_active Expired - Lifetime
- 2002-06-27 WO PCT/DK2002/000437 patent/WO2003002136A2/en not_active Ceased
- 2002-06-27 DE DE60224284T patent/DE60224284T2/de not_active Expired - Lifetime
2007
- 2007-04-11 US US11/786,095 patent/US20080167226A1/en not_active Abandoned
2008
- 2008-12-24 US US12/343,722 patent/US20090111752A1/en not_active Abandoned
2010
- 2010-05-24 US US12/785,861 patent/US8846618B2/en not_active Expired - Lifetime
2011
- 2011-09-26 JP JP2011209396A patent/JP2012051894A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
US8846618B2 (en)	2014-09-30
WO2003002136A2 (en)	2003-01-09
WO2003002136A3 (en)	2004-03-04
JP2012051894A (ja)	2012-03-15
EP1412384B1 (de)	2007-12-26
JP5562510B2 (ja)	2014-07-30
US20030119734A1 (en)	2003-06-26
DK1412384T3 (da)	2008-04-28
US20090111752A1 (en)	2009-04-30
EP1412384A2 (de)	2004-04-28
US20100234299A1 (en)	2010-09-16
DE60224284T2 (de)	2008-12-18
PT1412384E (pt)	2008-03-28
JP2004535442A (ja)	2004-11-25
AU2002316811A1 (en)	2003-03-03
ES2298378T3 (es)	2008-05-16
DE60224284D1 (de)	2008-02-07
US20080167226A1 (en)	2008-07-10

Legal Events

Date

Code

Title

Description

2008-06-15

UEP

Publication of translation of european patent specification

Ref document number: 1412384

Country of ref document: EP

Publication	Publication Date	Title
DE60224284D1 (de)	2008-02-07	Stabile formulierung von modifiziertem glp-1
CY1108532T1 (el)	2014-04-09	Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων
DE60235083D1 (de)	2010-03-04	Substituierte tetracyclin-verbindungen zur behandlung von malaria
IS6520A (is)	2002-08-22	Ný efnasambönd
EE200300475A (et)	2004-02-16	Türosiini kinaasi inhibiitorid, neid sisaldavad ravimkoostised ja nimetatud ühendid kasutamiseks haiguste ravis
PA8575701A1 (es)	2004-02-07	Preparaciones acidas de insulina con estabilidad mejorada
ATE449079T1 (de)	2009-12-15	Pharmazeutische zusammensetzungen beinhaltend kristallsalze von 7-ä4-(4-fluorophenyl)-6- isopropyl-2-
EE04990B1 (et)	2008-04-15	HMG reduktaasi inhibiitorit sisaldavad farmatseutilised kompositsioonid, nende kasutamine ja saamismeetod
CY1106468T1 (el)	2012-01-25	Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης
ATE376832T1 (de)	2007-11-15	Verzögert freisetzende formulierungen von oxymorphon
ATE486587T1 (de)	2010-11-15	Formulierungen zur oralen verabreichung von wirkstoffen
DK1172114T3 (da)	2005-01-24	Stabile koncentrerede insulinpræparater til pulmonær indgivelse
EE05385B1 (et)	2011-02-15	LaiaspektrilisedÁ2-(asendatudÁamino)bensotiasoolsulfoonamiididÁkuiÁHIVÁproteaasiÁinhibiitorid,ÁnendeÁvalmistamismeetodÁjaÁkasutamineÁningÁfarmatseutilineÁkompositsioon
DE60301339D1 (de)	2005-09-22	Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen
DE60116359D1 (de)	2006-02-02	Kahalalid f formulierung
CY1105247T1 (el)	2010-03-03	Υποκατεστημενα παραγωγα c- κυκλοεξυλομεθυλαμινης
SE0102716D0 (sv)	2001-08-14	Novel compounds
NO20042563L (no)	2004-06-18	Preparatsammensetning som inneholder syreustabile fysiologisk aktive forbindelser og fremgangsmater til fremstilling derav
DE50115451D1 (de)	2010-06-02	Pharmazeutische zusammensetzung zur nasalen anwendung von fentanyl
EE200300501A (et)	2003-12-15	Ninna manustatavad imidasotriasinooni sisaldavad kompositsioonid
SE0003476D0 (sv)	2000-09-28	Compounds
DK1407780T3 (da)	2013-05-13	Farmaceutisk stabile hæmostatiske præparater
NO20054440L (no)	2005-09-26	Flytende formuleringer av tumornekrosefaktorbindende proteiner
ATE253359T1 (de)	2003-11-15	Antithrombotische mittel
DK1273301T3 (da)	2007-01-08	Farmaceutiske præparater baseret på aktive bestanddele der kan anvendes til ulovlig administration